Structure Therapeutics (GPCR) Stock Forecast, Price Target & Predictions

GPCR Stock Forecast

Structure Therapeutics stock forecast is as follows: an average price target of $99.00 (represents a 254.84% upside from GPCR’s last price of $27.90) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

GPCR Price Target

The average price target for Structure Therapeutics (GPCR) is $99.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $118.00 to $86.00. This represents a potential 254.84% upside from GPCR's last price of $27.90.

GPCR Analyst Ratings

Buy

According to 6 Wall Street analysts, Structure Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for GPCR stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Structure Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 23, 2024	Terence Flynn	Morgan Stanley	$118.00	$41.92	181.49%	322.94%
Sep 10, 2024	Yasmeen Rahimi	Piper Sandler	$93.00	$34.72	167.86%	233.33%
Aug 09, 2024	Jonathan Wolleben	JMP Securities	$86.00	$34.49	149.35%	208.24%
Jun 07, 2024	Evan Seigerman	BMO Capital	$100.00	$53.07	88.43%	258.42%
Apr 09, 2024	Prakhar Agrawal	Cantor Fitzgerald	$65.00	$44.41	46.36%	132.97%

The latest Structure Therapeutics stock forecast, released on Sep 23, 2024 by Terence Flynn from Morgan Stanley, set a price target of $118.00, which represents a 181.49% increase from the stock price at the time of the forecast ($41.92), and a 322.94% increase from GPCR last price ($27.90).

Structure Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	5
Avg Price Target	-	$118.00	$92.40
Last Closing Price	$27.90	$27.90	$27.90
Upside/Downside	-100.00%	322.94%	231.18%

In the current month, the average price target of Structure Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Structure Therapeutics's last price of $27.90. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 21, 2024	BMO Capital	Outperform	Outperform	Hold
Sep 23, 2024	Morgan Stanley		Overweight	Initialise
Sep 10, 2024	Piper Sandler	Overweight	Overweight	Hold
Aug 09, 2024	JMP Securities	Outperform	Outperform	Hold
Jun 07, 2024	BMO Capital	Outperform	Outperform	Hold
Apr 09, 2024	Cantor Fitzgerald		Overweight	Initialise
Oct 03, 2023	BMO Capital	Outperform	Outperform	Hold
Feb 28, 2023	Guggenheim		Buy	Initialise

Structure Therapeutics's last stock rating was published by BMO Capital on Oct 21, 2024. The company gave GPCR a "Outperform" rating, the same as its previous rate.

Structure Therapeutics Financial Forecast

Structure Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-
# Analysts	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-

Structure Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. GPCR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Structure Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict GPCR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Structure Therapeutics's previous annual EBITDA (undefined) of $NaN.

Structure Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-15.81M	$-15.81M	$-16.31M	$-16.31M	$-14.95M	$-19.27M	$-17.10M	$-16.31M	$-11.20M	$-9.02M	$-10.87M
High Forecast	$-15.81M	$-15.81M	$-16.31M	$-16.31M	$-14.95M	$-19.27M	$-17.10M	$-12.23M	$-8.87M	$-9.02M	$-10.87M
Low Forecast	$-15.81M	$-15.81M	$-16.31M	$-16.31M	$-14.95M	$-19.27M	$-17.10M	$-19.70M	$-14.47M	$-9.02M	$-10.87M
Surprise %	-	-	-	-	-	-	-	-	-	-	-

Structure Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GPCR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Structure Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-	-	-	-	-
SG&A	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-

Structure Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to GPCR last annual SG&A of $NaN (undefined).

Structure Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-0.32	$-0.32	$-0.33	$-0.33	$-0.30	$-0.39	$-0.35	$-0.33	$-0.23	$-0.18	$-0.22
High Forecast	$-0.32	$-0.32	$-0.33	$-0.33	$-0.30	$-0.39	$-0.35	$-0.25	$-0.18	$-0.18	$-0.22
Low Forecast	$-0.32	$-0.32	$-0.33	$-0.33	$-0.30	$-0.39	$-0.35	$-0.40	$-0.29	$-0.18	$-0.22
Surprise %	-	-	-	-	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Structure Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GPCR previous annual EPS of $NaN (undefined).

Structure Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
BMEA	Biomea Fusion	$4.64	$23.33	402.80%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
GPCR	Structure Therapeutics	$31.48	$99.00	214.49%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
MREO	Mereo BioPharma Group	$3.40	$8.00	135.29%	Buy
AMLX	Amylyx Pharmaceuticals	$4.28	$8.25	92.76%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
HOOK	HOOKIPA Pharma	$2.13	$3.00	40.85%	Buy
IRON	Disc Medicine	$65.00	$77.67	19.49%	Buy

GPCR Forecast FAQ

Is Structure Therapeutics a good buy?

Yes, according to 6 Wall Street analysts, Structure Therapeutics (GPCR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of GPCR's total ratings.

What is GPCR's price target?

Structure Therapeutics (GPCR) average price target is $99 with a range of $86 to $118, implying a 254.84% from its last price of $27.9. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Structure Therapeutics stock go up soon?

According to Wall Street analysts' prediction for GPCR stock, the company can go up by 254.84% (from the last price of $27.9 to the average price target of $99), up by 322.94% based on the highest stock price target, and up by 208.24% based on the lowest stock price target.

Can Structure Therapeutics stock reach $40?

GPCR's average twelve months analyst stock price target of $99 supports the claim that Structure Therapeutics can reach $40 in the near future.

What are Structure Therapeutics's analysts' financial forecasts?

Structure Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-67.622M (high $-63.545M, low $-71.019M), average SG&A $0 (high $0, low $0), and average EPS is $-1.369 (high $-1.286, low $-1.437). GPCR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-64.237M (high $-64.237M, low $-64.237M), average SG&A $0 (high $0, low $0), and average EPS is $-1.3 (high $-1.3, low $-1.3).